新加升降散治疗心血管神经症66例临床分析和研究

Clinical analysis and research on treating 66 cases of cardiovascular neurosis with the Xinjia Shengjiang San

目的:观察对心血管神经症患者应用新加升降散进行治疗的临床效果。方法:对我院自2008年11月～2011年11月以来,于我科治疗的200例心血管神经症患者患者临床资料进行回顾性分析,将其分为A(120例)B(80例)两组,对A组患者应用新加升降散进行治疗,对B组患者应用弥可保进行治疗,两组疗程均为15d,同时予以3个月的随访。结果:A组120例患者中,显效28例,有效84例,无效8例,总有效率达到93.3%;B组80例患者中,显效20例,有效36例,无效24例,其总有效率仅是70.0%,对两组相较,其差异呈显著性(P<0.05);A组患者经治疗后,其症状积分达到(4.23±3.35)分,B组患者经治疗后达到(7.12±3.56)分,对两组相较,其差异呈显著性(P<0.05)。结论:对心血管神经症患者应用新加升降散进行治疗,不仅安全方便,而且疗效确切,应予推广。

Objective： To observe the clinical effect of treating cardiovascular neurosis with the Xinjia Shengjiang San. Methods： The hospital treatment in our department since November 2008 to November 2011,200 cases of patients with cardiovascular neurosis clinical data were retrospectively analyzed and divided into A （120 cases） B （80 cases） two groups, group A patients were treated with the Xinjia Shengiiang San, and group B patients were given Methycobal for treatment, they were treated for 15 days, while give the three month follow up. Results： In group A of 120 patients, markedly in 28 cases, effective in 84 cases, ineffective in 8 cases, the total efficiency of 93.3%; and in group B of 80 patients, markedly in 20 cases, effective in 36 cases, and ineffective in 24 cases, the total efficiency is only 70.0% compared the two groups, the difference was significant （P〈0.05）; group A of patients after treatment, the symptom score （4.23 ±3.35） points, the group B of patients after treatment （7.12 ± 3.56） points, compared the two groups, the difference was significant （P〈0.05）. Conclusion： Treating cardiovascular neurosis with the Xinjia Shengiiang San is safety, convenience, and efficacy, it should be promoted.